Literature DB >> 24850910

Angiotensin II and canonical transient receptor potential-6 activation stimulate release of a signal transducer and activator of transcription 3-activating factor from mouse podocytes.

Mousa Abkhezr1, Stuart E Dryer2.   

Abstract

Previous studies have shown that the transcription factor signal transducer and activator of transcription-3 (STAT3) in podocytes plays an important role in progression of HIV nephropathy and in collapsing forms of glomerulonephritis. Here, we have observed that application of 100 nM angiotensin II (Ang II) to cultured podocytes for 6-24 hours causes a marked increase in the phosphorylation of STAT3 on tyrosine Y705 but has no effect on phosphorylation at serine S727. By contrast, Ang II treatment of short periods (20-60 minutes) caused a small but consistent suppression of tyrosine phosphylation of STAT3. A similar biphasic effect was seen after treatment with the diacylglycerol analog 1-oleoyl-2-acetyl-sn-glycerol (OAG), an agent that causes activation of Ca(2+)-permeable canonical transient receptor potential-6 (TRPC6) channels in podocytes. The stimulatory effects of Ang II on STAT3 phosphorylation were abolished by small-interfering RNA knockdown of TRPC6 and also by inhibitors of the Ca(2+)-dependent downstream enzymes calcineurin and Ca(2+)-calmodulin-dependent protein kinase II. The stimulatory effects of Ang II appear to be mediated by secretion and accumulation of an unknown factor into the surrounding medium, as they are no longer detected when medium is replaced every 2 hours even if Ang II is continuously present. By contrast, the inhibitory effect of Ang II on STAT3 phosphorylation persists with frequent medium changes. Experiments with neutralizing and inhibitory antibodies suggest that the STAT3 stimulatory factor secreted from podocytes is not interleukin-6, but also suggest that this factor exerts its actions through a receptor system that requires glycoprotein 130.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24850910     DOI: 10.1124/mol.114.092536

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Hedgehog pathway plays a vital role in HIV-induced epithelial-mesenchymal transition of podocyte.

Authors:  Xiqian Lan; Hongxiu Wen; Kang Cheng; Andrei Plagov; Seyedeh Shadafarin Marashi Shoshtari; Ashwani Malhotra; Pravin C Singhal
Journal:  Exp Cell Res       Date:  2017-01-31       Impact factor: 3.905

Review 2.  TRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseases.

Authors:  Daria V Ilatovskaya; Alexander Staruschenko
Journal:  Am J Physiol Renal Physiol       Date:  2015-06-17

3.  Interleukin-6 Downregulates the Expression of Vascular Endothelial-Cadherin and Increases Permeability in Renal Glomerular Endothelial Cells via the Trans-Signaling Pathway.

Authors:  Yong-Chang Yang; Hui Fu; Bo Zhang; Yu-Bin Wu
Journal:  Inflammation       Date:  2022-07-23       Impact factor: 4.657

Review 4.  "TRP inflammation" relationship in cardiovascular system.

Authors:  Tomohiro Numata; Kiriko Takahashi; Ryuji Inoue
Journal:  Semin Immunopathol       Date:  2015-10-19       Impact factor: 9.623

5.  The Role of Angiotensin II in Glomerular Volume Dynamics and Podocyte Calcium Handling.

Authors:  Daria V Ilatovskaya; Oleg Palygin; Vladislav Levchenko; Bradley T Endres; Alexander Staruschenko
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

Review 6.  Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update.

Authors:  Hua Su; Chun-Tao Lei; Chun Zhang
Journal:  Front Immunol       Date:  2017-04-21       Impact factor: 7.561

7.  Podocyte injury in diabetic nephropathy: implications of angiotensin II-dependent activation of TRPC channels.

Authors:  Daria V Ilatovskaya; Vladislav Levchenko; Andrea Lowing; Leonid S Shuyskiy; Oleg Palygin; Alexander Staruschenko
Journal:  Sci Rep       Date:  2015-12-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.